Tobacco product giant Philip Morris International Inc. trims its life sciences industry footprint to developing and commercializing consumer health and wellness oral formulations and inhaled Rx drugs as it divests subsidiary Vectura Group's medical device segment.
For less than a third of the £1.1bn ($1.45bn) PMI paid for Vectura Group in 2021, it is divesting the...